Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI

Not Recruiting

Trial ID: NCT00537056

Purpose

To learn whether Flourine-18 Fluoro-deoxi-glucose positron emission tomography / computed tomography (F-18 FDG PET/CT) and dynamic contrast enhanced magnetic resonance imaging (DCE MRI) are better predictors of response to therapy than the current standard of care (CT or MRI).

Official Title

Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI

Stanford Investigator(s)

Robert Herfkens
Robert Herfkens

Professor of Radiology (Cardiovascular Imaging), Emeritus

Sandy Srinivas
Sandy Srinivas

Professor of Medicine (Oncology) and, by courtesy, of Urology

Eligibility


Inclusion Criteria:- Measurable disease by RECIST criteria

   - Pathologic diagnosis of renal cell cancer

   - Advanced (stage IV) renal cell cancer

   - Karnofsky performance status of (KPS>70)

   - Consent to participate in the clinical trial Exclusion Criteria:- Patients who cannot
   complete a PET/CT scan.

   - Pregnant women.

   - Healthy volunteers.

   - Patients participating in other research protocols will be excluded from this study.

   - Metallic implants (prosthesis, ICD, pacemakers), since these are contraindications for
   MRI.

Intervention(s):

procedure: FDG PET CT

procedure: DCE MRI

drug: F-18 Fluoro-deoxi-glucose

drug: Gadolinium-DTPA

drug: Sunitinib

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Andrew Quon
6507361369

New Trial Alerts

Receive email alerts when trials open to patients.